Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) EBIT: 2016-2025

Historic EBIT for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to -$52.2 million.

  • Rocket Pharmaceuticals' EBIT rose 24.74% to -$52.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$250.5 million, marking a year-over-year increase of 8.51%. This contributed to the annual value of -$273.2 million for FY2024, which is 5.22% down from last year.
  • According to the latest figures from Q3 2025, Rocket Pharmaceuticals' EBIT is -$52.2 million, which was up 26.57% from -$71.1 million recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' EBIT ranged from a high of -$34.0 million in Q2 2021 and a low of -$73.7 million during Q2 2024.
  • Moreover, its 3-year median value for EBIT was -$65.4 million (2023), whereas its average is -$65.5 million.
  • Over the last 5 years, Rocket Pharmaceuticals' EBIT had its largest YoY gain of 25.16% in 2021, and its largest YoY loss of 81.28% in 2021.
  • Quarterly analysis of 5 years shows Rocket Pharmaceuticals' EBIT stood at -$44.3 million in 2021, then crashed by 55.83% to -$69.1 million in 2022, then increased by 8.40% to -$63.3 million in 2023, then increased by 0.92% to -$62.7 million in 2024, then increased by 24.74% to -$52.2 million in 2025.
  • Its last three reported values are -$52.2 million in Q3 2025, -$71.1 million for Q2 2025, and -$64.4 million during Q1 2025.